NKTX [NASD]
Nkarta, Inc.
Index- P/E- EPS (ttm)-2.81 Insider Own0.90% Shs Outstand32.99M Perf Week13.34%
Market Cap622.50M Forward P/E- EPS next Y-2.89 Insider Trans- Shs Float20.89M Perf Month-8.57%
Income-92.70M PEG- EPS next Q-0.61 Inst Own55.60% Short Float26.24% Perf Quarter10.08%
Sales- P/S- EPS this Y51.80% Inst Trans8.77% Short Ratio1.67 Perf Half Y-8.21%
Book/sh6.93 P/B1.99 EPS next Y-3.60% ROA-31.40% Target Price46.50 Perf Year-53.07%
Cash/sh4.79 P/C2.87 EPS next 5Y- ROE-35.70% 52W Range7.55 - 40.64 Perf YTD-10.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.16% Beta-
Dividend %- Quick Ratio20.60 Sales past 5Y- Gross Margin- 52W Low87.55% ATR1.01
Employees135 Current Ratio20.60 Sales Q/Q- Oper. Margin- RSI (14)57.80 Volatility7.20% 7.82%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.10% Profit Margin- Rel Volume0.05 Prev Close13.76
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume3.28M Price14.16
Recom1.70 SMA209.34% SMA500.37% SMA200-1.63% Volume19,076 Change2.91%
Mar-11-22Initiated Raymond James Outperform $17
Mar-08-22Initiated H.C. Wainwright Buy $25
Jan-06-22Initiated William Blair Outperform
Nov-18-21Initiated SMBC Nikko Outperform $50
Jul-16-21Initiated Oppenheimer Outperform $75
Aug-04-20Initiated Stifel Buy $41
Aug-04-20Initiated Mizuho Buy $34
Aug-04-20Initiated Evercore ISI Outperform $55
Aug-04-20Initiated Cowen Outperform
Jun-14-22 07:14AM  
Jun-07-22 09:55AM  
May-31-22 07:02AM  
May-18-22 12:00PM  
09:55AM  
May-16-22 04:02PM  
May-12-22 04:02PM  
May-09-22 04:02PM  
May-06-22 05:30PM  
May-02-22 10:45AM  
Apr-28-22 04:01PM  
10:18AM  
Apr-25-22 11:19PM  
06:04PM  
05:44PM  
04:09PM  
04:01PM  
03:52PM  
10:49AM  
08:34AM  
08:19AM  
07:12AM  
07:00AM  
Apr-22-22 04:10PM  
Apr-17-22 08:54AM  
Apr-08-22 01:25PM  
07:58AM  
Apr-04-22 12:00PM  
Mar-29-22 08:02AM  
Mar-22-22 10:00AM  
Mar-17-22 04:02PM  
Mar-08-22 04:35PM  
Mar-01-22 11:00AM  
Feb-10-22 08:02AM  
Jan-05-22 06:56AM  
Dec-16-21 08:02AM  
Dec-13-21 04:02PM  
Nov-25-21 07:35AM  
Nov-15-21 10:47AM  
Nov-12-21 07:15AM  
Nov-10-21 04:01PM  
Nov-04-21 08:04AM  
Oct-08-21 08:11AM  
Oct-07-21 04:01PM  
09:24AM  
Oct-01-21 08:08AM  
Sep-14-21 08:32AM  
Aug-12-21 04:02PM  
Jul-14-21 09:07AM  
07:00AM  
Jun-16-21 07:00AM  
Jun-14-21 07:01AM  
Jun-06-21 12:16PM  
May-25-21 07:30AM  
May-13-21 04:02PM  
May-07-21 11:38AM  
May-06-21 04:01PM  
Apr-28-21 08:02AM  
Mar-25-21 04:03PM  
Feb-17-21 04:03PM  
Dec-09-20 03:46PM  
Dec-07-20 03:33PM  
Nov-12-20 04:03PM  
04:02PM  
Nov-09-20 08:02AM  
Nov-05-20 04:02PM  
Oct-12-20 11:03AM  
Oct-05-20 04:02PM  
Sep-29-20 08:02AM  
Sep-08-20 04:02PM  
Aug-20-20 04:02PM  
Jul-31-20 04:42PM  
Jul-14-20 04:39PM  
04:15PM  
Jul-10-20 11:30AM  
08:09AM  
12:44AM  
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brandenberger RalphSr. VP, Technical OperationsJun 03Option Exercise3.694,14015,2789,440Jun 07 04:01 PM
Brandenberger RalphSr. VP, Technical OperationsJun 03Sale15.004,14062,1005,300Jun 07 04:01 PM
George SimeonDirectorApr 28Buy15.001,333,33319,999,995666,667Apr 29 04:27 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 26Buy15.002,200,00033,000,0007,805,129Apr 28 04:32 PM
Brandenberger RalphSr. VP, Technical OperationsDec 01Option Exercise3.694,14015,2784,140Dec 03 05:02 PM
Brandenberger RalphSr. VP, Technical OperationsDec 01Sale15.644,14064,7500Dec 03 05:02 PM
HASTINGS PAUL JChief Executive OfficerSep 29Sale27.188,500231,051219,061Oct 01 04:35 PM
Brandenberger RalphSee RemarksSep 01Option Exercise3.694,14015,2784,140Sep 02 08:52 PM
Brandenberger RalphSee RemarksSep 01Sale32.084,140132,8110Sep 02 08:52 PM
Rajangam KanyaChief Medical OfficerAug 05Option Exercise0.4110,0004,10010,000Aug 09 05:17 PM
Rajangam KanyaChief Medical OfficerAug 05Sale37.2810,000372,8000Aug 09 05:17 PM
Trager JamesChief Scientific OfficerAug 02Option Exercise3.892,2508,75247,972Aug 04 04:50 PM
Trager JamesChief Scientific OfficerAug 02Sale31.533,600113,50844,372Aug 04 04:50 PM